NASDAQ:ARWR

Arrowhead Pharmaceuticals Stock Forecast, Price & News

$89.51
+1.42 (+1.61 %)
(As of 06/24/2021 04:30 PM ET)
Add
Compare
Today's Range
$88.48
$90.40
50-Day Range
$65.66
$89.81
52-Week Range
$32.86
$93.66
Volume704,957 shs
Average Volume784,555 shs
Market Capitalization$9.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.28
30 days | 90 days | 365 days | Advanced Chart
Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals logo

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.07 out of 5 stars

Medical Sector

1065th out of 2,105 stocks

Pharmaceutical Preparations Industry

504th out of 832 stocks

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

Is Arrowhead Pharmaceuticals a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Arrowhead Pharmaceuticals?

Wall Street analysts have given Arrowhead Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arrowhead Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Arrowhead Pharmaceuticals
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings results on Monday, May, 3rd. The biotechnology company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.17. The biotechnology company had revenue of $32.81 million for the quarter, compared to analyst estimates of $39.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 23.64% and a negative net margin of 122.97%. Arrowhead Pharmaceuticals's revenue was up 39.4% on a year-over-year basis.
View Arrowhead Pharmaceuticals' earnings history
.

How has Arrowhead Pharmaceuticals' stock been impacted by COVID-19?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARWR stock has increased by 213.4% and is now trading at $89.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARWR?

11 brokers have issued 1-year price objectives for Arrowhead Pharmaceuticals' stock. Their forecasts range from $34.00 to $110.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $88.42 in the next twelve months. This suggests that the stock has a possible downside of 1.2%.
View analysts' price targets for Arrowhead Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 52, Pay $1.61M)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 55, Pay $690.3k)
  • Dr. Javier San Martin, Chief Medical Officer (Age 56, Pay $673.57k)
  • Mr. James Hassard, Chief Commercial Officer (Age 54, Pay $488.3k)
  • Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson, Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone, VP of Investor Relations
  • Mr. Patrick O'Brien, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 57)
  • Mr. Howard Lovy, Director of Communications
  • Dr. James C. Hamilton, Sr. VP of Discovery & Translational Medicine (Age 43)

Who are some of Arrowhead Pharmaceuticals' key competitors?

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.39%), JPMorgan Chase & Co. (2.47%), Geode Capital Management LLC (1.69%), Northern Trust Corp (1.49%), Credit Suisse AG (1.43%) and Fiera Capital Corp (1.20%). Company insiders that own Arrowhead Pharmaceuticals stock include Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals
.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Nomura Holdings Inc., Nuveen Asset Management LLC, First Light Asset Management LLC, Morgan Stanley, First Manhattan Co., Citigroup Inc., and State of Tennessee Treasury Department. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien, and William D Waddill.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Oak Ridge Investments LLC, BlackRock Inc., Bamco Inc. NY, Renaissance Technologies LLC, Voloridge Investment Management LLC, Principal Financial Group Inc., and Principal Financial Group Inc..
View insider buying and selling activity for Arrowhead Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $89.52.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals has a market capitalization of $9.32 billion and generates $87.99 million in revenue each year. The biotechnology company earns $-84,550,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 232 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Where are Arrowhead Pharmaceuticals' headquarters?

Arrowhead Pharmaceuticals is headquartered at 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.